MedTrace Logo

Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

NCT03861715 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2020-10-08

No results posted yet for this study

Summary

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

Conditions

Interventions

DIAGNOSTIC_TEST

live birth rate

The blastulation rate and live birth rate according to the protocol of COS

Sponsors & Collaborators

  • Assisting Nature

    lead OTHER

Principal Investigators

  • Evaggelos Papanikolaou, MD, PhD · Assisting Nature

  • Robert Najdecki, MD, PhD · Assisting Nature

Eligibility

Min Age
20 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03861715 on ClinicalTrials.gov